18605319. REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA (President and Fellows of Harvard College)

REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA

Organization Name

President and Fellows of Harvard College

Inventor(s)

Julian Solway of Chicago IL (US)

Nickolai Dulin of Chicago IL (US)

Marsha Rosner of Chicago IL (US)

Gokhan Mutlu of Chicago IL (US)

Diane Luci of Bethesda MD (US)

David Maloney of Bethesda MD (US)

Chan Young Park of Cambridge MA (US)

Jeffrey Fredberg of Cambridge MA (US)

David Mccormick of Chicago IL (US)

Ramaswamy Krishnan of Boston MA (US)

REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA

This abstract first appeared for US patent application 18605319 titled 'REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA

Original Abstract Submitted

Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.